Background and Aims: In the Phase 3 RAISE study (NCT04115293), zilucoplan, a complement component 5 inhibitor, demonstrated clinically meaningful improvements in myasthenia gravis (MG)‐specific outcomes versus placebo in patients with anti‐acetylcholine receptor antibody‐positive generalised MG (gMG); improvements were sustained during long‐term use in the ongoing open‐label extension study, RAISE‐XT (NCT04225871). The gene discussed is C5; the disease is myasthenia gravis.